DexCom, Inc. (NASDAQ:DXCM) Holdings Lowered by Martin Currie Ltd.

Martin Currie Ltd. trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 15.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 95,071 shares of the medical device company’s stock after selling 17,412 shares during the period. Martin Currie Ltd.’s holdings in DexCom were worth $6,492,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Bank Pictet & Cie Europe AG raised its position in DexCom by 1.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company’s stock valued at $8,637,000 after purchasing an additional 2,010 shares during the last quarter. Mariner LLC raised its position in DexCom by 1.5% in the 4th quarter. Mariner LLC now owns 29,729 shares of the medical device company’s stock valued at $2,312,000 after purchasing an additional 442 shares during the last quarter. United Capital Financial Advisors LLC raised its position in DexCom by 56.9% in the 4th quarter. United Capital Financial Advisors LLC now owns 17,649 shares of the medical device company’s stock valued at $1,373,000 after purchasing an additional 6,401 shares during the last quarter. Finally, NewEdge Advisors LLC raised its position in DexCom by 122.5% in the 4th quarter. NewEdge Advisors LLC now owns 23,905 shares of the medical device company’s stock valued at $1,859,000 after purchasing an additional 13,159 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of DXCM opened at $79.96 on Friday. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The firm has a fifty day simple moving average of $83.17 and a two-hundred day simple moving average of $80.14. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The firm has a market cap of $31.36 billion, a PE ratio of 55.53, a P/E/G ratio of 1.68 and a beta of 1.43.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.43 EPS. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the completion of the sale, the director directly owned 33,411 shares in the company, valued at $2,766,430.80. This trade represents a 9.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 6,184 shares of the firm’s stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total transaction of $526,320.24. Following the completion of the sale, the executive vice president owned 109,621 shares of the company’s stock, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,656 shares of company stock valued at $2,412,191 in the last ninety days. Company insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of analyst reports. The Goldman Sachs Group initiated coverage on DexCom in a research note on Friday, May 30th. They set a “buy” rating and a $104.00 price objective for the company. Barclays lifted their price objective on DexCom from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 30th. Robert W. Baird decreased their price objective on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Canaccord Genuity Group reaffirmed a “buy” rating and set a $106.00 price objective on shares of DexCom in a research note on Friday, August 1st. Finally, Morgan Stanley increased their price target on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.